New hope for Parkinson's: drug pump study targets early advanced patients
NCT ID NCT07227896
First seen Nov 13, 2025 · Last updated May 18, 2026 · Updated 26 times
Summary
This study looks at how well the drug Foslevodopa/Foscarbidopa works for people with early advanced Parkinson's disease. About 100 adults will receive the drug as a continuous infusion under the skin for up to 6 months. Researchers will track changes in daily 'off' time (when symptoms return) and movement problems using questionnaires. The goal is to see if starting this treatment earlier helps control symptoms better in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Boston Medical Center Health System
Boston, Massachusetts, 02118, United States
Conditions
Explore the condition pages connected to this study.